Draft Agenda @ 30th August 2018

09:00 – 09:30 Registration

09:30 – 09:45 Welcome David Hartley, The XLP Research Trust

**XLP1**

09:45 – 10:05 **CD8 defects in XLP1 and Activated P13 Kinase Syndrome**

Dr. Pamela Schwartzberg, NHGRI and NIAID, Bethesda, USA

10:05 – 10:25 **Diacylglycerol kinase-alpha is an effector of SAP/NCK1/WASP/Arp2/3 signalling pathway regulating cytoskeleton remodelling and Restimulation Cell Death (RICD)**

Dr. Andrea Graziani, Università Vita-Salute S. Raffaele, Milan, Italy

10:25 – 10:45 **Novel DGKα Inhibitors for XLP1 therapy via virtual screening**

Assoc. Prof. Gianluca Baldanzi, Dept. Translational Medicine, Novara, Italy

10:45 to 11:15 Coffee break
11:15 – 11:35  **Modification of cellular and humoral immunity by somatically reverted T cells in XLP1**

Prof. Hirokazu Kanegane, Tokyo Medical and Dental University, Tokyo, Japan

11:35 – 12:05  **Developing novel T cell therapies for XLP1**

Dr. Neelam Panchal, UCL-GOSICH, London, UK

12:05 – 12:25  **TALEN-mediated genome editing via AAV6 donor in T cells for the treatment of X-linked lymphoproliferative disease (XLP)**

Dr. Ben Houghton, UCL Great Ormond Street Institute of Child Health, London

12:25 – 13:30  Lunch

13:30 – 13:50  **Update on The XLP Research Trust**

David Hartley, Chairman & Co-Founder

**XIAP**

13:50 – 14:10  **Critical role of T-cell expansion in immunity to EBV revealed by genetic defects with high predisposition to EBV infection**

Dr. Sylvain Latour, Institute Imagine, Paris, France

14:10 – 14:30  **Determining anti-viral immune responses and cell death pathways in XIAP deficiencies**

Dr. Lynn Wong, Institute of Experimental Immunology, University of Zurich, Switzerland

14:30 – 14:50  **Dysregulated IL 1-beta secretion in XIAP deficiency is abrogated by the natural flavonoid quercetin**

Dr. Rebecca Marsh, Cincinnati Children’s Hospital, USA
14:50 – 15:15  Tea Break

15:15 – 15:35  **XIAP deficiency and inflammatory bowel disease**
    Dr. Holm Uhlig, Oxford University, UK

15:35 – 15:55  **An update on outcome following Haematopoietic stem cell transplantation in XIAP deficiency**
    Dr. Austen Worth, Great Ormond Street Hospital, London, UK

15:55 – 16:15  **Correction of innate immune responses in XIAP deficiency using gene modified haematopoietic stem cells**
    Yusef Topal, UCL Great Ormond Street Institute of Child Health

16:15       Wrap Up

16:30       Mingle

We’d again like to thank the Jeffrey Modell Foundation for awarding is a WIN grant to reduce the cost of the symposium.